Everything dog owners need to know about Librela (bedinvetmab) — what it is, how it works, real cost, side effects reported to the FDA, the safety warnings issued in 2025, and the honest answers to every question pet owners are asking. Vet-sourced. Unsponsored. Always in your dog’s corner.
Librela (bedinvetmab injection), made by Zoetis, is the first monoclonal antibody the FDA has ever approved for use in dogs. Approved on May 5, 2023, and launched commercially in October 2023, it represents a fundamentally different approach to managing arthritis pain in dogs — instead of a daily pill, it is a once-monthly injection given by your veterinarian that works by blocking a specific protein responsible for pain signaling. Osteoarthritis (OA) affects an estimated 25–40% of dogs at some point in their lives and is one of the most common reasons aging dogs become less active and lose quality of life. Librela has helped many dogs significantly. It has also generated serious safety reports that the FDA formally communicated to veterinarians in early 2025, resulting in label updates. Understanding both sides is essential before making a decision with your vet.
This guide is for educational purposes only. It does not constitute veterinary advice for your individual dog. All decisions about Librela must be made in consultation with a licensed veterinarian who knows your dog’s full medical history. If your dog has already received Librela and is showing new or concerning symptoms, contact your veterinarian immediately.
-
1
What is Librela and how does it work? Librela (bedinvetmab) is a once-monthly injectable monoclonal antibody that controls arthritis pain in dogs by binding to and blocking nerve growth factor (NGF) — a protein elevated in dogs with OA that transmits pain signals to the brain.The FDA approved Librela on May 5, 2023, making it the first monoclonal antibody approved for use in dogs in the United States. Per the FDA’s approval announcement and the Freedom of Information Summary (NADA 141-562): bedinvetmab works by binding to canine nerve growth factor (NGF) with high affinity, preventing it from communicating pain signals to the brain. NGF is found to be elevated in dogs with OA and is a key driver of chronic joint pain. The dosage is weight-based: 0.5 mg/kg (0.23 mg/lb) of body weight, administered as a subcutaneous (under the skin) injection once a month. Librela is not a steroid, not an NSAID, and does not treat inflammation — it specifically interrupts the pain signaling pathway. It does not cure or reverse osteoarthritis.
-
2
Is Librela the same as gabapentin? No — Librela and gabapentin are completely different medications with different mechanisms, forms, and uses. Librela is a monthly injectable monoclonal antibody; gabapentin is a daily oral anticonvulsant/nerve pain pill. They may sometimes be used together as part of a multimodal pain plan.Librela (bedinvetmab) is a biologic medication — a lab-created antibody protein injected subcutaneously once monthly. It targets nerve growth factor (NGF) specifically. Gabapentin is a small-molecule anticonvulsant drug taken orally (capsule or tablet) typically once to three times daily. Gabapentin works on calcium channels in the nervous system to broadly reduce nerve excitability, while Librela precisely targets one protein involved in OA pain. PetMD (April 2025) and GoodRx (August 2025) confirm these are distinct medications. In some pain management protocols, veterinarians use both together — Librela for OA joint pain and gabapentin for additional nerve pain modulation — but your vet will determine the appropriate plan for your individual dog.
-
3
What are the side effects of Librela for dogs? The most common clinical study side effects were urinary tract infections, bacterial skin infections, and dermatitis. Post-approval FDA reports identified more serious events: ataxia (unsteady gait), seizures, hind leg weakness, urinary incontinence, excessive thirst/urination, vomiting, and in some cases death.The FDA issued a formal “Dear Veterinarian Letter” in late 2024 after evaluating adverse event reports. Per the AVMA (February 2025): as of April 18, 2024, the FDA’s database included 3,674 adverse event reports associated with Librela. Two-thirds of these reports indicated signs occurring within the first week after administration, with 30% occurring within the first day. Signs were observed after the initial dose in 70% of reported cases. The adverse events included: ataxia, seizures, paresis (partial paralysis), recumbency (inability to stand), urinary incontinence, polyuria (excessive urination), and polydipsia (excessive thirst). In some cases, death or euthanasia was reported. The FDA and Zoetis subsequently updated the drug label on February 18, 2025, with expanded warnings and a new Client Information Sheet. Adverse events globally occur at a reported rate of 1–10 per 10,000 doses distributed, per Zoetis’s own statement.
-
4
Can Librela cause hind leg weakness? Yes — hind leg weakness, ataxia (unsteady gait), and hind limb paresis have been reported to the FDA following Librela injections and are specifically listed in the updated February 2025 drug label warnings.The FDA’s adverse event analysis (published September 2024) includes specific documented cases: one report describes a dog developing hind limb ataxia, hind limb weakness, and hind limb muscle tremors 24 hours after the second dose. Austin Canine Rehab (July 2025) explains a plausible biological mechanism: Librela blocks nerve growth factor (NGF) throughout the body, not just in arthritic joints. If a dog has an underlying nerve compression issue, spinal disease, or intervertebral disc disease (IVDD), blocking NGF can potentially interfere with nerve repair mechanisms and mask pain signals that would otherwise limit damaging activity. This is why the AKC (October 2025), citing Dr. Leilani Alvarez of NYC’s Schwarzman Animal Medical Center, specifically states the drug should not be used in dogs with suspected neurological conditions or existing hind-end weakness. If your dog develops any new neurological signs after a Librela injection, contact your veterinarian immediately.
-
5
Is Librela any good for dogs — does it actually work? For the right candidate, yes. FDA field studies showed meaningful pain reduction in dogs with osteoarthritis. In both the U.S. and EU studies, Librela-treated dogs had higher rates of improvement than placebo dogs, with benefits increasing with each monthly dose.The FDA’s Freedom of Information Summary for NADA 141-562 reports the clinical study results: in the EU field study (281 dogs), there was a statistically significant difference between Librela-treated dogs and controls at Day 28 (p < 0.05). In both studies, the percentage of dogs achieving treatment success was higher in the Librela group at Day 42 and Day 84 (after three doses) than at Day 28 — meaning results improve with continued monthly dosing. Zoetis data indicates some dogs may see improvement as early as 7 days after the first injection, though full benefit may not be evident until after the second dose. The AKC (October 2025) cites Dr. Patsy Mich, DVM, DACVAA, DACVSMR: “The ideal candidate for Librela has uncomplicated osteoarthritis — overall healthy without concurrent neurological symptoms or conditions.” Librela is particularly valuable for dogs who cannot tolerate NSAIDs due to gastrointestinal or kidney issues, since it operates through a completely different pathway.
-
6
How much does Librela cost per month? Approximately $90–$220 per monthly injection in the U.S. (2025–2026), depending on dog size. Larger dogs cost more because dosing is weight-based and Librela comes in fixed-size single-use vials. Additional vet visit or exam fees may apply on top of the injection cost.SpectrumCare’s March 2026 cost guide confirms: in the United States in 2025–2026, many pet owners can expect the Librela injection itself to cost approximately $90–$220 per month at general practice clinics. Small dogs tend to be near the lower end; giant-breed dogs may be at the higher end or above it, because the dose is based on body weight and Librela is supplied in fixed single-use vials (5, 10, 15, 20, and 30 mg/mL). Dogs at certain weight thresholds may require two vials. Newsweek (December 2024) reported a similar range of $60–$150 per injection from estimates at the time. On top of the injection cost, some clinics charge separately for the administration, vet exam, or required monitoring bloodwork. This is an ongoing monthly expense — not a one-time cost.
-
7
Where can I buy Librela for dogs? Librela is a prescription medication that can only be purchased through and administered by a licensed veterinarian. It is not available for purchase online, at pet stores, or for home use. Your vet must both prescribe and administer each injection.PetMD (April 2025), reviewed by Dr. Molly Price DVM (Texas A&M College of Veterinary Medicine), is explicit: “Librela is available only by prescription and must be administered at a veterinary practice. It is not available for administration at home because your vet’s professional expertise is needed to properly diagnose pain associated with osteoarthritis in your dog, administer the injection, and monitor the safe use of Librela.” The drug is available in 5, 10, 15, 20, and 30 mg/mL single-use vials, and is dispensed as a prescription animal drug (NADA 141-562, Zoetis). Any website advertising Librela for home purchase or delivery without a direct veterinary prescription should be viewed with extreme caution. The requirement for in-office administration also allows the vet to monitor for immediate reactions — some vets observe dogs for 30 minutes after the first three injections.
-
8
Is there a Librela lawsuit? Yes. A lawsuit was filed in New Jersey alleging that Zoetis misrepresented Librela as safe without adequately disclosing significant adverse effects. The allegations have not been tested in court. Zoetis has defended the drug’s safety profile.The Globe and Mail (November 2024) reported on a class action lawsuit filed in New Jersey against Zoetis, alleging the company’s advertising and promotional materials represented Librela as safe “without disclosing many significant adverse effects associated with the product” and that Zoetis “has downplayed safety issues” related to the drug. The newspaper spoke with eight dog owners whose pets’ health declined after receiving Librela, including one dog whose hind legs lost function entirely for four months after the second injection. Zoetis’s response, according to the Globe and Mail: the company stated the FDA’s Dear Vet Letter was not a “warning” but a “safety update” and that the drug had been rigorously tested. The lawsuit allegations have not been proven in court. The FDA’s label update in February 2025 followed these reports and the accumulation of post-approval adverse event data.
-
9
Which dogs should NOT receive Librela? Dogs with neurological conditions (IVDD, degenerative myelopathy), existing hind-end weakness, pregnancy, breeding or lactating status, known hypersensitivity to bedinvetmab, or a history of cruciate ligament rupture within 6 months should not receive Librela. Dogs under 12 months old have not been evaluated.The FDA-approved prescribing information and the updated February 2025 label both list contraindications. The AKC (October 2025), citing Dr. Leilani Alvarez (Schwarzman Animal Medical Center, NYC) and Dr. Patsy Mich (pain management specialist): dogs with intervertebral disc disease, degenerative myelopathy, or lumbosacral stenosis are not suitable candidates. The drug has not been evaluated for postoperative pain management, for spinal pain, or for pain from torn ligaments. It should not be used concurrently with other NSAIDs without established safety data (the safety of anti-NGF monoclonal antibodies with concurrent NSAIDs has not been established in dogs, per the FDA package insert). Breeding, pregnant, and lactating dogs must not receive Librela. Women who are pregnant, trying to conceive, or breastfeeding should take extreme care to avoid accidental self-injection due to risk of hypersensitivity reactions including anaphylaxis.
-
10
What are the pros and cons of Librela for dogs? Pros: once-monthly injection (no daily pills), a genuinely different pain pathway (useful when NSAIDs fail or are contraindicated), proven effectiveness in FDA trials, improving pain relief with each dose. Cons: significant post-approval safety concerns, unknown long-term effects beyond 9 months, high monthly cost, can only be given by a vet.SpectrumCare (March 2026) and the AKC (October 2025) both provide balanced assessments. Key advantages: convenient once-monthly dosing is easier than remembering a daily pill; it offers a non-NSAID pain pathway that is genuinely useful for dogs with kidney disease, GI issues, or those who have failed NSAIDs; and its effectiveness tends to improve over the first three months of use. Key disadvantages: the FDA label itself states that “long-term effects which may occur more than 9 months after the use of Librela have not been evaluated”; post-approval adverse events including neurological signs, hind leg weakness, and death have been reported; it can only be given at a vet office (monthly appointment required); it cannot be given to dogs with neurological disease; and the $90–$220/month ongoing cost is significant. The AKC notes that in rare cases, 1–10 per 10,000 dogs develop loss of efficacy due to formation of anti-bedinvetmab antibodies.
Sources: FDA.gov CVM Approval Announcement May 5 2023 (bedinvetmab first mAb for dogs; NGF mechanism; OA prevalence 25%); FDA Freedom of Information Summary NADA 141-562 (dosing 0.5 mg/kg; field study results Day 28/42/84; safety studies; contraindications; long-term effects not evaluated beyond 9 months); FDA Dear Veterinarian Letter (adverse events: ataxia, seizures, paresis, urinary incontinence, polyuria, polydipsia, death; 3,674 reports through Apr 18 2024; 70% first week; 30% first day); AVMA News / JAVMA Feb 2025 (FDA Dear Vet Letter confirmed; adverse event submission to Zoetis 1-888-963-8471); American College of Veterinary Pharmacists Apr 2025 NADA 141-562 (label update Feb 18 2025; Client Information Sheet new); PetMD / Dr. Molly Price DVM (Texas A&M) Apr 18 2025 (prescription only; in-office only; mAb definition; anti-bedinvetmab antibody formation); AKC Expert Advice Oct 2025 (Dr. Leilani Alvarez DVM Schwarzman AMC NYC; Dr. Patsy Mich DVM DACVAA DACVSMR; ideal candidate uncomplicated OA; 30-min observation first 3 doses; no IVDD/DM/lumbosacral; no postop use); GoodRx Pet Health / Dr. Sarah Wooten DVM CVJ Aug 2025 (Librela vs gabapentin different mechanisms; label update 2025); SpectrumCare Librela Cost Guide Mar 2026 (cost $90–$220/month US 2025–2026; weight-based vial sizes); Newsweek Dec 2024 (cost $60–$150 per injection; Dear Vet Letter coverage; 1–10/10,000 dose AE rate Zoetis); Globe and Mail Nov 2024 (NJ lawsuit Zoetis; owner accounts hind leg loss; not proven in court); Austin Canine Rehab Jul 2025 (neurological caution; NGF nerve repair mechanism; IVDD/DM contraindication); Zoetis Petcare official / Client Info Sheet Jan 2025 (contraindications: pregnant/breeding/lactating; accidental injection women; adverse events rate)
In late 2024, the FDA’s Center for Veterinary Medicine issued a formal “Dear Veterinarian Letter” after analyzing adverse events reported in dogs treated with Librela. As of April 18, 2024, the FDA database contained 3,674 adverse event reports. The adverse events identified included: ataxia (unsteady movements), seizures, paresis (partial paralysis), recumbency (inability to stand), urinary incontinence, polyuria (excessive urination), polydipsia (excessive thirst), and death including euthanasia. Two-thirds of reports indicated signs occurring within the first week of administration, with 30% within the first day, and 70% of cases showing signs after the initial dose. These reports do not definitively prove causation — many affected dogs were older and may have had concurrent conditions — but the FDA found the pattern significant enough to require formal communication to veterinarians and a label update.
On February 18, 2025, Zoetis updated the U.S. Librela label (NADA 141-562) to reflect post-approval data. Per the American College of Veterinary Pharmacists (April 2025): key changes include a requirement for veterinarians to provide the Client Information Sheet to pet owners before administration, a discussion of potential adverse events prior to giving the injection, and expanded guidance on what owners should monitor after treatment. The updated label now specifically calls out signs requiring prompt veterinary attention: balance problems, trouble walking, weakness, trouble standing, paralysis, seizures, increased drinking, increased urination, loss of bladder control, vomiting, or diarrhea. Some serious events occurred with or without warning and some dogs died. The label also notes that long-term effects occurring more than 9 months after use have not been evaluated.
The Zoetis official prescribing information and Client Information Sheet carry a specific warning for humans: Women who are pregnant, trying to conceive, or breastfeeding should take extreme care to avoid accidental self-injection with Librela. Accidental self-injection can cause hypersensitivity reactions, including anaphylaxis. This warning applies to owners in the vet’s office when the injection is being prepared or administered, as well as to anyone handling vials. This is a standard safety precaution for injectable biologic medications.
If your dog experiences any concerning reaction after receiving Librela, you can report it through two channels. First, contact Zoetis directly at 1-888-963-8471 (the manufacturer is required to report all adverse events to the FDA). When you call, provide your dog’s medical history, the number of doses administered, and the lot number from the vial. Second, you or your veterinarian can also report directly to the FDA CVM online reporting system at fda.gov/animal-veterinary. Reporting adverse events — even if you are unsure whether Librela caused them — helps the FDA monitor drug safety across the entire population of treated animals. This data directly drives label updates and safety communications like the Dear Vet Letter issued in 2024.
Sources: FDA CVM Dear Veterinarian Letter (fda.gov/animal-veterinary; 3,674 reports through Apr 18 2024; adverse event list; pattern analysis); FDA adverse event analysis download Sep 2024 (case series 363; 70% first week; 30% first day; hind limb ataxia case within 24 hours second dose); American College of Veterinary Pharmacists Apr 8 2025 (label update Feb 18 2025; Client Info Sheet requirement; NADA 141-562); SpectrumCare Mar 2026 (label update summary; signs requiring immediate vet attention; long-term effects 9 months not evaluated); Zoetis Petcare official Client Information Sheet Jan 2025 (women pregnant warning; accidental injection anaphylaxis; adverse event rate 1–10/10,000 doses); AVMA News Feb 2025 (Dear Vet Letter confirmed; reporting to Zoetis 1-888-963-8471; lot number requirement)
Is Librela Right for Your Dog? A Quick Reference
| Dog’s Situation | Librela Appropriate? | Reason |
|---|---|---|
| Confirmed OA in limb joints, no neurological disease | ✔ Good Candidate | Approved indication; best clinical outcomes |
| Cannot tolerate NSAIDs (kidney/GI issues) | ✔ Often Recommended | Different pathway; doesn’t rely on NSAID tolerance |
| Existing IVDD or degenerative myelopathy | ✘ Not Recommended | May worsen neurological signs; blocks nerve repair |
| Hind leg weakness or coordination problems | ✘ Use Extreme Caution | FDA adverse events; may exacerbate neurological signs |
| Pregnant, breeding, or lactating dog | ✘ Contraindicated | Official label contraindication per Zoetis/FDA |
| Dog under 12 months old | ⚠ Not Evaluated | Safety/effectiveness not studied in dogs under 1 year |
| Cruciate ligament rupture within 6 months | ⚠ Not Evaluated | Excluded from clinical studies; consult vet |
| Spinal pain or post-surgical pain | ✘ Not Appropriate | Only evaluated for limb joint OA; spinal use unstudied |
| Receiving other NSAIDs concurrently | ⚠ Not Established Safe | FDA label: safe concurrent NSAID use not established in dogs |
Sources: FDA package insert / prescribing information NADA 141-562 (contraindications; dogs under 12 months; cruciate exclusion; NSAID safety not established); AKC Oct 2025 / Dr. Leilani Alvarez DVM; Dr. Patsy Mich DVM DACVAA DACVSMR (ideal candidate; IVDD/DM exclusion; spinal pain exclusion; postop pain exclusion); SpectrumCare Mar 2026 (cost $90–$220; vet-only administration); PetMD Apr 2025 (in-office only; weight-based dosing; vial sizes)
Before agreeing to Librela, SpectrumCare (March 2026) recommends asking your vet the following: Is my dog’s pain confirmed to be from osteoarthritis, or do we need X-rays or other testing first? Does my dog have any neurological conditions or hind-end weakness that would make Librela risky? Has my dog had baseline bloodwork including kidney function values? What specific side effects should I watch for, and how quickly should I contact you if I see them? What is the monitoring plan if my dog is on Librela for several months? Are there alternative options if Librela isn’t appropriate? And critically: request the Client Information Sheet — veterinarians are now required by the updated label to provide it and discuss risks before each administration.
Some dogs show improvement as early as 7 days after the first injection. However, per the FDA field study data and Zoetis’s prescribing information: maximum effectiveness may not be seen until after the second dose (approximately 28–42 days into treatment). Both the U.S. and EU clinical studies showed that the percentage of dogs achieving treatment success continued to improve through Day 84 (after three monthly doses). The AKC (October 2025) notes that if you have not seen meaningful improvement in your dog after two full doses, you should discuss alternative or additional treatment options with your veterinarian. Because Librela has an average half-life of approximately 19 days, it takes several weeks to clear the body after stopping injections — meaning potential adverse effects do not resolve immediately if the drug is discontinued.
Several effective alternatives exist depending on your dog’s specific situation. NSAIDs (carprofen, meloxicam, grapiprant/Galliprant) remain the most widely used first-line treatments for OA pain in dogs. Gabapentin is used for nerve pain modulation and is often part of a multimodal approach. Adequan injections (polysulfated glycosaminoglycan) help protect joint cartilage and are given as an injectable series followed by maintenance doses. Physical rehabilitation, including controlled exercise, hydrotherapy, and laser therapy, can meaningfully improve mobility. Joint supplements (omega-3 fatty acids, glucosamine, chondroitin) have supportive evidence for mild-to-moderate OA. Weight management is one of the most impactful interventions for OA — reducing body weight by 10–15% in overweight dogs can dramatically improve mobility. Many vets use a combination of these approaches rather than a single medication alone.
Contact your veterinarian immediately — do not wait to see if it improves on its own. Hind leg weakness, ataxia, trouble standing, or sudden changes in coordination after a Librela injection are listed in the updated February 2025 drug label as signs requiring prompt veterinary attention. Per SpectrumCare (March 2026): see your vet immediately if your dog seems weak, wobbly, unable to rise, has a seizure, loses bladder control, or has any sudden change after an injection. Your veterinarian will assess whether the signs are related to Librela or to an underlying condition. Because Librela has a half-life of approximately 19 days, the drug remains active for weeks after an injection, so the body must metabolize it out naturally after the final dose — it cannot be reversed. For owners who believe their dog has had a serious reaction, report it to Zoetis at 1-888-963-8471 and to the FDA through fda.gov/animal-veterinary.
Sources: SpectrumCare Mar 2026 (questions for vet before Librela; signs requiring immediate attention; half-life 19 days); AKC Oct 2025 (improvement timeline; Dr. Alvarez two-dose evaluation); FDA prescribing information NADA 141-562 (half-life; NSAIDs concurrent use not established); AVMA / FDA Dear Vet Letter (reporting to Zoetis 1-888-963-8471; lot number); PetMD Apr 2025 (anti-bedinvetmab antibodies reducing efficacy); GoodRx Aug 2025 (Adequan; gabapentin alternatives); Austin Canine Rehab Jul 2025 (NGF nerve repair; caution neurological dogs; half-life implications)
Find veterinary clinics that prescribe Librela, canine rehabilitation specialists, and emergency vet services near you. Allow location access when prompted for local results.
- Step 1: Confirm the diagnosis with your vet — make sure OA in the limb joints is the actual source of pain. Weakness, wobbliness, and reluctance to move can also be caused by neurological conditions, cruciate injuries, or spinal disease that Librela is not appropriate for and could potentially worsen. X-rays or an orthopedic exam may be needed to confirm the diagnosis before starting treatment.
- Step 2: Discuss your dog’s complete health history — especially any neurological signs, back problems, or existing weakness. The February 2025 updated label and FDA Dear Vet Letter specifically flag dogs with neurological conditions as being at higher risk for serious adverse events. Any history of IVDD, degenerative myelopathy, or hind-end changes must be disclosed and considered.
- Step 3: Ask about baseline bloodwork including kidney function (BUN and creatinine) before starting. Elevated BUN (blood urea nitrogen) was one of the adverse events observed in clinical studies, and some vets recommend a baseline to monitor changes over time on the drug.
- Step 4: Request and read the Client Information Sheet from Zoetis. As of February 2025, veterinarians are required to provide this to you before administration. It lists what to monitor after each injection and when to seek veterinary attention. Know the warning signs before your dog receives the first dose: balance problems, trouble walking, weakness, seizures, loss of bladder control, sudden increased thirst or urination, vomiting.
- Step 5: Have Zoetis’s and the FDA’s reporting numbers saved before you leave the clinic. Zoetis adverse event reporting: 1-888-963-8471. FDA CVM online: fda.gov/animal-veterinary. If your dog shows any concerning signs after an injection, report them even if you are unsure whether Librela caused them — this data directly informs drug safety monitoring and future label updates.
- Any new neurological signs in the days following an injection. Unsteady walking, hind leg weakness, dragging legs, stumbling, falling, or inability to rise are the most serious reported adverse events. The FDA data shows that 70% of concerning cases showed signs within the first week, and 30% within the first day. Do not assume these are unrelated to Librela because your vet told you it was safe — contact your vet and report the event.
- Sudden increases in water consumption or urination, or loss of bladder control. Polyuria, polydipsia, and urinary incontinence are among the adverse events specifically listed in the updated 2025 label. These can also indicate kidney involvement. Mention any such changes to your vet at the next visit or sooner if they are dramatic.
- Watch for signs of Librela losing effectiveness over time. PetMD (April 2025) notes that some dogs develop anti-bedinvetmab antibodies that can reduce the drug’s effectiveness over time. If your dog’s arthritis pain appears to worsen after initially responding to Librela, inform your vet promptly so the treatment plan can be reassessed.
© BestiePaws.com — This guide is independently researched and written. We are not affiliated with, sponsored by, compensated by, or endorsed by Zoetis, Inc. or any veterinary product manufacturer. No affiliate links or payments of any kind. All medical information, FDA data, adverse event statistics, and clinical study results were sourced from official government, veterinary medical association, and DVM-reviewed sources as of April 2026. This content is educational and does not constitute veterinary advice for your individual dog. Always consult a licensed veterinarian before starting, continuing, or stopping any medication for your pet. Report adverse events: Zoetis 1-888-963-8471 • FDA CVM: fda.gov/animal-veterinary • AVMA (find a vet): avma.org/veterinarians/find-a-vet • FDA Librela adverse events: fda.gov/animal-veterinary/product-safety-information
Primary sources: FDA.gov CVM Approval Announcement May 5 2023; FDA Freedom of Information Summary NADA 141-562 May 2023 (dosing; field studies; safety; contraindications; long-term effects 9 months not evaluated); FDA Dear Veterinarian Letter (adverse events: ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, polydipsia, death; 3,674 reports through Apr 18 2024; reporting 1-888-963-8471); FDA CVM adverse event analysis download Sep 2024 (363 case series; 70% first week; 30% first day; 70% first dose; hind limb ataxia 24-hr case); AVMA News / JAVMA Feb 2025 (Dear Vet Letter; FDA data confirmed; reporting instructions); American College of Veterinary Pharmacists Apr 8 2025 (label update Feb 18 2025; NADA 141-562; Client Info Sheet mandate; veterinarian education requirement); PetMD / Dr. Molly Price DVM Texas A&M Apr 18 2025 (prescription only; vet-only administration; anti-bedinvetmab antibodies; mAb mechanism); AKC Expert Advice Oct 2025 (Dr. Leilani Alvarez DVM Schwarzman Animal Medical Center NYC; Dr. Patsy Mich DVM MS DABVP DACVAA DACVSMR CCRT; ideal candidate uncomplicated OA; IVDD/DM/lumbosacral exclusion; no postop; 30-min observation first 3 doses; 1–10/10,000 efficacy loss); GoodRx Pet Health / Dr. Sarah Wooten DVM CVJ Aug 2025 (Librela ≠ gabapentin; mechanisms different; label update 2025); SpectrumCare Librela Cost Guide Mar 2026 (cost $90–$220/month US 2025–2026; weight-based vials; vet-only administration; 2025 label warning signs; half-life 19 days); Newsweek Dec 2024 (cost $60–$150/injection; Dear Vet Letter coverage; Zoetis statement; 1–10/10,000 AE rate); Globe and Mail Nov 2024 (NJ lawsuit Zoetis; owner accounts; allegations not proven in court); Austin Canine Rehab Jul 2025 (NGF nerve repair mechanism; IVDD/DM contraindication; hind-end weakness caution; half-life implications); Frontiers in Veterinary Science May 9 2025 (musculoskeletal adverse events bedinvetmab; PMID 40417367); Zoetis Petcare official / Client Info Sheet Jan 2025 (contraindications breeding/pregnant/lactating; women accidental injection warning; adverse event rate 1–10/10,000 doses; effectiveness; side effects)